TScan Therapeutics, Inc.TCRXNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank50
3Y CAGR+207.4%
5Y CAGR-49.7%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+207.4%/yr
Annual compound
5Y CAGR
-49.7%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 6.93 | -92.5% |
| 2024 | 92.03 | +467.2% |
| 2023 | 16.23 | +6695.1% |
| 2022 | 0.24 | +105.1% |
| 2021 | -4.71 | -102.2% |
| 2020 | 216.13 | - |
| 2019 | 0.00 | - |